Logo
x

Search

Subscribe Now

Bayer

Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

  • November 22, 2024
Bayer Join Forces with Cytokinetics to Develop and Commercialize Aficamten in Japan

Bayer Join Forces with Cytokinetics to Develop and Commercialize Aficamten in Japan

  • November 19, 2024
Bayer Reports the Regulatory Submission of Nubeqa (Darolutamide) to the EMA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Bayer Reports the Regulatory Submission of Nubeqa (Darolutamide) to the EMA for Treating Metastatic Hormone-Sensitive Prostate Can...

  • October 14, 2024
Bayer Collaborates with MOMA Therapeutics for the Development of a Small Molecule Oncology Program

Bayer Collaborates with MOMA Therapeutics for the Development of a Small Molecule Oncology Program

  • October 9, 2024
Bayer Reports Regulatory Submission of Nubeqa to the US FDA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Bayer Reports Regulatory Submission of Nubeqa to the US FDA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

  • September 26, 2024
Bayer Reports the P-III (OASIS 3) Trial Data of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women

Bayer Reports the P-III (OASIS 3) Trial Data of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women

  • September 11, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.